Stanford University researchers have created long-term human lung organoids that retain a built-in, functioning immune system — a advance that could transform how scientists study COVID-19 and other respiratory diseases. The work, published in Nature on October 7, 2026, used intact fragments of adult human lung tissue from more than 220 donors.
According to the National Institutes of Health, which funded the study, the team cultured the tissue in a 3D air-liquid interface system that mimics the lung's gas-exchange environment, sustaining the organoids for up to several months. Critical immune cell populations thrived inside the structures, and the resident T cells maintained their virus-sensing capabilities over extended periods — something previous organoid models could not achieve.
When the researchers infected the organoids with SARS-CoV-2, the models mounted both generic inflammatory responses and adaptive, virus-specific T cell reactions. In a simulated vaccination experiment, pre-stimulating the organoids with viral fragments taught the resident immune cells to detect and dispatch the virus more efficiently, weakening subsequent infections.
"These organoids retain key immune cells and functions of lung mucosa long term, allowing investigators to examine local tissue immunity separately from the other parts of the body's immune system," said Dr. John H. Powers III, acting director of NIH's National Institute of Allergy and Infectious Diseases. MedicalXpress reported that Powers added the platform "may provide a replacement for animal models for some types of evaluations" and capture insights animal tests cannot.
The findings add to growing evidence that the lung mucosa's own immune defenses provide significant protection — supporting the development of mucosal vaccines that train the respiratory tract's frontline defenders. The team believes the models could also illuminate tissue-level immunity in COPD, asthma, and bacterial infections.
The NIH-funded study also demonstrated that the organoids could be used to test vaccine candidates directly on human lung tissue, potentially accelerating the development of next-generation mucosal vaccines designed to block SARS-CoV-2 at its point of entry. According to the researchers, such local vaccines could one day complement or even replace traditional injections that induce systemic immunity.